Search - tctmd.com

Displaying 41 - 60 of 306

Sort: Relevancy | Date

Presentation THT 2025

Interatrial versus Coronary Sinus Shunting: Device and Procedural Comparisons

Presenter: Kamran Muhammad

February 11, 2025

Presentation THT 2025

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial

Presenter: Barry Borlaug

February 11, 2025

Presentation THT 2025

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Presenter: Gregg W. Stone

February 11, 2025

Presentation THT 2025

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Presenter: Ibrahim Kamel

February 11, 2025

Presentation THT 2025

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFpEF Patients

Presenter: James Udelson

February 11, 2025

Presentation THT 2025

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF

Presenter: Barry Borlaug

February 11, 2025

Presentation THT 2025

Is There a Difference in the Benefits of AF Ablation in HFrEF vs HFpEF?

Presenter: Andrea Russo

February 11, 2025

Presentation THT 2025

Obese HFpEF Patients Exhibit Distinct Augmentation Patterns of VO2 Components During Exercise

Presenter: Takenori Ikoma

February 11, 2025

Presentation THT 2025

How Regulation of Stressed Blood Volume at Rest and Exercise Contributes to HFpEF Symptomatology

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Assessing Determinants of Maximal Exercise Tolerance: What Are the Relative Contributions of PCWP, Ventilatory Anaerobic Threshold and Lactate

Presenter: Yogesh Reddy

February 11, 2025

Presentation THT 2025

Setting Pace in HFpEF: The Rationale for Personalized Heart Rates

Presenter: Harriette Van Spall

February 11, 2025

Presentation THT 2025

Insights Into Hemodynamic Mechanisms of HFpEF From Advanced Invasive Hemodynamic Measurements

Presenter: Philipp Lurz

February 11, 2025

Presentation THT 2025

Session Introduction: Novel Frontiers in HFpEF Diagnostics and Management

Presenter: Kavita Sharma

February 11, 2025

Presentation THT 2025

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Presenter: Jeffrey Testani

February 11, 2025

Presentation THT 2025

Comprehensive Mapping of Exercise Hemodynamic Responses and Multi-Organ System Reserve Capacity in HFpEF and Implications for Individualized Management

Presenter: Isabela Landsteiner

February 11, 2025

Presentation THT 2025

Mechanisms by Which Cardiometablic Drugs Help People Feel Better

Presenter: Barry Borlaug

February 11, 2025

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

L.A. McKeown

February 01, 2025

News Daily News

NT-proBNP Cutoffs for HFpEF Diagnosis May Need Tweaking

Todd Neale

January 29, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

Advertisement

Interatrial versus Coronary Sinus Shunting: Device and Procedural Comparisons

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Mechanistic Observations of How an Atrial Shunt Impacts the Hearts of HFpEF Patients

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF

Is There a Difference in the Benefits of AF Ablation in HFrEF vs HFpEF?

Obese HFpEF Patients Exhibit Distinct Augmentation Patterns of VO2 Components During Exercise

How Regulation of Stressed Blood Volume at Rest and Exercise Contributes to HFpEF Symptomatology

Assessing Determinants of Maximal Exercise Tolerance: What Are the Relative Contributions of PCWP, Ventilatory Anaerobic Threshold and Lactate

Setting Pace in HFpEF: The Rationale for Personalized Heart Rates

Insights Into Hemodynamic Mechanisms of HFpEF From Advanced Invasive Hemodynamic Measurements

Session Introduction: Novel Frontiers in HFpEF Diagnostics and Management

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Comprehensive Mapping of Exercise Hemodynamic Responses and Multi-Organ System Reserve Capacity in HFpEF and Implications for Individualized Management

Mechanisms by Which Cardiometablic Drugs Help People Feel Better

February 2025 Dispatch for the CV Team

NT-proBNP Cutoffs for HFpEF Diagnosis May Need Tweaking

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content